Avenue Therapeutics Inc.
| NASDAQ: ATXI |
| Healthcare / Biotechnology / USA |
| 0.3129 | -0.0250 | -7.40% | Vol 65.70K | 1Y Perf -92.23% |
| May 18th, 2022 16:00 DELAYED |
| BID | 0.3101 | ASK | 0.3399 | ||
| Open | 0.3500 | Previous Close | 0.3379 | ||
| Pre-Market | - | After-Market | 0.31 | ||
| - - | - -% |
| Target Price | 9.00 | Analyst Rating | — 0.00 | |
| Potential % | 2.78K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 2.26 | Earnings Rating | Neutral | |
| Market Cap | 6.80M | Earnings Date | 5th Jan 2022 | |
| Alpha | -0.03 | Standard Deviation | 0.25 | |
| Beta | 1.04 |
Today's Price Range 0.31260.3500 | 52W Range 0.20005.19 | 5 Year PE Ratio Range -9.50-3.30 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 6.26% | ||
| 1 Month | -28.62% | ||
| 3 Months | 28.48% | ||
| 6 Months | -73.18% | ||
| 1 Year | -92.23% | ||
| 3 Years | -92.81% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -144.39 | |||
ROE last 12 Months | -132.14 | |||
ROA (5Y Avg) | -199.31 | |||
ROA last 12 Months | -106.89 | |||
ROC (5Y Avg) | -293.36 | |||
ROC last 12 Months | -128.67 | |||
Return on invested Capital Q | -55.55 | |||
Return on invested Capital Y | -55.55 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.50 | ||||
| 2.13 | ||||
| - | ||||
| - | ||||
| -3.00 | ||||
| -0.22 | ||||
| 2.13 | ||||
| 0.16 | ||||
| 3.58M | ||||
| Forward PE | -1.84 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 7.60 | ||||
| 7.80 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2020 | -0.10 | -0.06 | 40.00 |
| Q02 2020 | -0.10 | -0.11 | -10.00 |
| Q01 2020 | -0.17 | -0.08 | 52.94 |
| Q04 2019 | - | -0.32 | - |
| Q03 2019 | -0.32 | -0.14 | 56.25 |
| Q02 2019 | -0.57 | -0.43 | 24.56 |
| Q01 2019 | -0.44 | -0.82 | -86.36 |
| Q04 2018 | -0.47 | -0.38 | 19.15 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2021 QR | -0.05 | 0.00 | - |
| 12/2021 QR | -0.04 | 20.00 | Positive |
| 12/2021 FY | -0.20 | -300.00 | Negative |
| 12/2022 FY | -0.18 | 14.29 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 65.70K |
| Shares Outstanding | 21.73K |
| Shares Float | 11.59M |
| Trades Count | 211 |
| Dollar Volume | 22.23K |
| Avg. Volume | 1.82M |
| Avg. Weekly Volume | 160.65K |
| Avg. Monthly Volume | 271.05K |
| Avg. Quarterly Volume | 5.02M |
Avenue Therapeutics Inc. (NASDAQ: ATXI) stock closed at 0.3379 per share at the end of the most recent trading day (a 1.75% change compared to the prior day closing price) with a volume of 141.53K shares and market capitalization of 6.80M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 4 people. Avenue Therapeutics Inc. CEO is Lucy Lu.
The one-year performance of Avenue Therapeutics Inc. stock is -92.23%, while year-to-date (YTD) performance is -62.79%. ATXI stock has a five-year performance of %. Its 52-week range is between 0.2 and 5.185, which gives ATXI stock a 52-week price range ratio of 2.26%
Avenue Therapeutics Inc. currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 2.13, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -106.89%, a ROC of -128.67% and a ROE of -132.14%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Avenue Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Avenue Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Avenue Therapeutics Inc. is — (0), with a target price of $9, which is +2 776.32% compared to the current price. The earnings rating for Avenue Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Avenue Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Avenue Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.54, ATR14 : 0.05, CCI20 : -59.99, Chaikin Money Flow : -0.12, MACD : -0.05, Money Flow Index : 32.36, ROC : -8.60, RSI : 37.67, STOCH (14,3) : 56.23, STOCH RSI : 1.00, UO : 53.51, Williams %R : -43.77), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Avenue Therapeutics Inc. in the last 12-months were: Joseph Vazzano (Sold 7 160 shares of value $11 599 )
Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of an intravenous, or IV, formulation of tramadol HCl, or IV Tramadol, for the management of postoperative pain.
CEO: Lucy Lu
Telephone: +1 781 652-4500
Address: 1140 Avenue of the Americas, New York 10036, NY, US
Number of employees: 4
